Congestive Heart Failure Treatment Landscape: FDA Approves Enbumyst, First Self-Administered Loop Diuretic | DelveInsight's Perspective on Market Impact, Competitive Landscape and Pipeline Therapies

DelveInsight Business Research's analysis underscores the transformative implications of the FDA's approval of ENBUMYST (bumetanide nasal spray) by Corstasis Therapeutics Inc. (NASDAQ: CORT). This landmark decision delivers the first self-administered outpatient alternative to intravenous loop diuretics, promising enhanced convenience for the ~21 million adults living with congestive heart failure (CHF) in the 7MM.
Key Congestive Heart Failure Market Highlights

*
Enbumyst's approval is poised to be a Congestive Heart Failure market driver, expanding diuretic delivery beyond inpatient settings.

*
In 2023, the Congestive Heart Failure treatment market in the 7MM was valued at USD 6.9 billion, with the US representing the largest share.

*
Congestive Heart Failure affects ~21 million patients across the US, EU4, UK and Japan, with rising prevalence driven by an aging population and improved survival in ischemic heart disease.

*
Leading CHF companies include Novartis (ENTRESTO), AstraZeneca (FORXIGA), Eli Lilly (MOUNJARO), Boehringer Ingelheim & Lilly (JARDIANCE), and Merck (VERQUVO).

Explore DelveInsight's in-depth Congestive Heart Failure Market Report [https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] to understand shifting treatment dynamics and the role of Enbumyst in reshaping fluid management.

Market Impact and Congestive Heart Failure Patient Population

DelveInsight's Congestive Heart Failure Market Insight, Epidemiology and Market Forecast [https://www.delveinsight.com/report-store/congestive-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] report details a chronic progressive condition characterized by fluid overload and elevated diastolic pressures. While current treatments rely on oral diuretics, ACE inhibitors, ARBs, beta-blockers and SGLT2 inhibitors, Enbumyst offers an innovative modality for more efficient outpatient fluid management, addressing a key unmet need.

According to the report, heart failure with preserved ejection fraction (HFpEF) accounts for ~50% of patients, underscoring the demand for convenient symptomatic therapies. Generics of furosemide dominate the oral loop diuretic segment, posing a challenge for novel entrants but highlighting the significance of an alternative delivery route.

Request a DelveInsight's Congestive Heart Failure Epidemiology & Market Intelligence report [https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] to assess unmet needs, patient population trends, and revenue potential.

Enbumyst Treatment Approach

Enbumyst combines bumetanide, a potent loop diuretic, with a nasal spray formulation enabling rapid mucosal absorption. Unlike intravenous bumetanide requiring healthcare-supervised infusions, Enbumyst provides:

*
Self-administration via a metered nasal device

*
Onset of diuresis within 15-30 minutes, comparable to IV formulations

*
Potential to reduce hospital visits, improve patient autonomy, and lower healthcare costs

"Enbumyst empowers patients to manage fluid overload at home, reducing the burden on infusion centers," said Dr. Amanda Lee, Principal Investigator in ambulatory heart failure care.

Enbumyst Clinical Validation and Efficacy

FDA approval was based on data from the pivotal Phase III NASCARDIA study, which enrolled 320 adults with chronic CHF (NYHA Class II-III). Key findings included:

*
Mean daily weight loss of 1.2 kg versus 0.3 kg with oral furosemide (p



This release was published on openPR.